BREAST CANCER TYPING USING RT-PCR ASSAY

 Introduction. Adjuvant systemic therapy remains one of the main options for treating breast cancer. Results of standard immunohistochemical studies are not always a criterion for selecting systemic therapy. Nowadays, multigene expression analysis is actively used to predict the response to chemotherapy in patients with earlystage breast cancer. We studied a 24-gene multi-gene panel for typing breast cancer.

Material and Methods. A prospective analysis of 199 breast cancer patients (T1–3N0–3M0) was carried out. Surgical specimens were studied using the standard immunohistochemistry (IHC) and RT-PCR for detecting expression of 24 genes.

Results. According to the IHC results, breast cancer was divided into 5 molecular subtypes: luminal A was detected in 59 (30 %) patients; luminal B (HER2-negative) in 52 (26 %); luminal B (HER2-positive) in 19 (9 %); triple-negative in 28 (14 %); HER2-positive 41 (21 %). RT-PCR showed that ST K15, MYC, MYBL2, BIRCC 5, BCL2, TERT, ESRP1, PGR, HER2, GBR7, MGB1 and MMP11 were the most significant genes in subtype distribution. The total percentage of matches between the two studies was 61.7 %.

Conclusion. Studies have shown the need to add additional typing methods for breast cancer to a standard IHC study, which will undoubtedly increase the information content of diagnostic measures and will improve the effectiveness of the treatment.

1. Stenina M.B., Frolova M.A., Kupchan D.Z., Tyulyandin S.A. Changes in neoand adjuvant treatment of breast cancer in last 5 years. Practical oncology. 2017; 18 (3): 256–264. (in Russian). doi: 10.31917/1803256.

2. Bragina O.D., Slonimskaya E.M., Zavyalova M.V., Telegina N.S., Perelmuter V.M., Tarabanovskaya N.A., Doroshenko A.V. The predictive value of a number of molecular parameters in patients with basal-like triple-negative breast cancer. Siberian Journal of Oncology. 2014; 3: 5–10. (in Russian)

3. Babyshkina N., Malinovskaya E., Cherdyntseva N., Patalyak S., Bragina O., Tarabanovskaya N., Doroshenko A., Slonimskaya E., Perelmuter V. Neoadjuvant chemotherapy for different molecular breast cancer subtypes: a retrospective study in Russian population. Medical Oncology. 2014; 31(9): 1–12. doi: 10.1007/s12032-014-0165-7.

4. Zavyalova M., Vtorushin S., Krakhmal N., Savelieva O., Tashireva L., Kaigorodova E., Perelmuter V., Telegina N., Denisov E., Bragina O., Slonimskaya E., Choynzonov E. Clinicopathological features of nonspecific invasive breast cancer according to its molecular subtypes. Experimental Oncology. 2016; 38 (2): 122–127. doi: 10.31768/2312-8852.

5. Van Hellemond I.E.G., Geurts S.M.E., Tjan-Heijnen V.C.G. Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer. Current Treatment Options in Oncology. 2018; 19 (5): 1–18. doi: 10.1007/s11864-018-0541-1.

6. Chernov V.I., Bragina O.D., Sinilkin I.G., Medvedeva A.A., Zel’chan R.V. Radioimmunotherapy in the treatment of malignancies. Siberian journal of oncology. The predictive value of a number of molecular parameters in patients with basal-like triple-negative breast cancer. Siberian Journal of Oncology. 2016; 15 (2): 101–106. (in Russian).

7. Untch M., Huober J., Jackisch C., Schneeweiss A., Brucker S.Y., Dall P., Denkert C., Fasching P.A., Fehm T., Gerber B., Janni W., Kühn T., Lüftner D., Möbus V., Müller V., Rody A., Sinn P., Thill M., Thomssen C., Harbeck N., Liedtke C. Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017). Geburtshilfe Und Frauenheilkunde. 2017; 77(6): 633–644. doi: 10.1055/s-0043-111601.

8. Cianfrocca M., Gradishar W. New Molecular Classifications of Breast Cancer. CA Cancer J Clin. 2009; 59(5): 303–313. doi: 10.3322/caac.20029.

9. Vorobyeva A., Bragina O., Altai M., Mitran B., Orlova A., Shulga A., Proshkina G., Chernov V., Tolmachev V., Deyev S. Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors. Contrast Media & Molecular Imaging. 2018. 2018. 6930425. doi: 10.1155/2018/6930425.

10. Coates A.S., Winer E.P., Goldhirsch A., Gelber R.D., Gnant M., Piccart-Gebhart M., Thürlimann B., Senn H.J. Panel Members. Panel Members. Tailoring therapies improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol. 2015; 26 (8):1533–46. doi: 10.1093/annonc/mdv221.

11. Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D., PiccartGebhart M., Thürlimann B., Senn H.J. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol. 2013; 24 (9): 2206–2223. doi: 10.1093/annonc/mdt303.

12. Rossi L., McCartney A., De Santo I., Risi E., Moretti E., Malorni L., Biganzoli L., Di Leo A. The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review. Cancer Treat Rev. 2019; 24: 29–34. doi: 10.1016/j.ctrv.2019.01.007.

13. Cardoso F., van't Veer L.J., Bogaerts J., Slaets L., Viale G., Delaloge S., Pierga J.Y., Brain E., Causeret S., DeLorenzi M., Glas A.M., Golfinopoulos V., Goulioti T., Knox S., Matos E., Meulemans B., Neijenhuis P.A., Nitz U., Passalacqua R., Ravdin P., Rubio I.T., Saghatchian M., Smilde T.J., Sotiriou C., Stork L., Straehle C., Thomas G., Thompson A.M., van der Hoeven J.M., Vuylsteke P., Bernards R., Tryfonidis K., Rutgers E., Piccart M. 70 gene signature as an aid to treatment decisions in early stage breast cancer. N Engl J Med. 2016; 375(8): 717–729. doi: 10.1056/NEJMoa1602253.

14. Hequet D., Callens C., Gentien D., Albaud B., Mouret-Reynier M.A., Dubot C., Cottu P., Huchon C., Zilberman S., Berseneff H., Foa C., Salmon R., Roulot A., Lerebours F., Salomon A., Ghali N., Morel P., Li Q., Cayre A., Guinebretière J.M., Hornberger J., Penault-Llorca F., Rouzier R. Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers. PLoS One. 2017; 12 (10): 0185753. doi: 10.1371/journal.pone.0185753.

15. Otsuji K., Sasaki T., Tanaka A., Kunita A., Ikemura M., Matsusaka K., Tada K., Fukayama M., Seto Y. Use of droplet digital PCR for quantitative and automatic analysis of the HER2 status in breast cancer patients. Breast Cancer Res Treat. 2017; 162 (1): 11–18. doi: 10.1007/s10549016-4092-5.

16. Minegishi Y., Uchiyama K., Sakurai K., Ibe S., Kanda H., Nihonyanagi S., Nakamura M., Ikeda S., Takaso M. Clinical usefulness of multiplex PCR-lateral flow for the diagnosis of orthopedic-related infections. Mod Rheumatol. 2018; 5: 1–7. doi: 10.1080/14397595.2018.1514690.

17. Bozhenko V.K., Kudinova E.A. Analysis of gene expression of proliferation and apoptosis depending on the status of steroid hormone receptors in breast cancer. Russian Scientific Center of Roentgenoradiology. 2012; 12 (4): 23. (in Russian).

18. Dergunova Y.A., Kometova V.V., Bozhenko V.K., Vardanyan S.G., Kulinich T.M., Rodionov V.V., Kudinova E.A. Comparison of the immunohistochemical and PCR methods for determining the level of Ki67 expression in breast cancer tissue.. Russian Scientific Center of Roentgenoradiology. 2018; 18 (3): 52–68. (in Russian)